← All candidates
5 insider filings on record.
5 filings on record.
VTGNVistagen Therapeutics, Inc.
NasdaqCM · Healthcare · $10.52M
$0.2400
5 insider filings on record.
None of them an open-market buy in the last year.
No price data yet — the yfinance scanner hasn't produced bars for VTGN.
AI brief · from the filings on this pagePro
The filings, the score and the setup on this page, read for you in about ten seconds — what the insiders did, and what stands against it.
Market cap
$10.52M
Float
41.4M
93% public
Short % float
Pro
Price / profit
—
not yet profitable
Price / future profit
—
Price / sales
4.2
The record
newest first
DateTypeInsiderOf stakeShares @ priceValue
Context
Wall St
$0.9667 avg target
+302.8% vs today · 3 analysts · consensus Hold
▸ relayed analyst opinion, which tends to run optimistic — not our forecast or advice
Earnings · EPS vs forecast
1 of 4 quarters beat
Q1 '26−$0.37 act−$0.10
Q4 '25−$0.45 act+$0.03
Q3 '25−$0.54 act−$0.10
Q2 '25−$0.47 act−$0.03
Coverage
Is Vistagen Therapeutics, Inc. (VTGN) a Breakout Anxiety Drug Stock After New Phase 3 Extension Results?Insider Monkey · 05-19VistaGen Therapeutics, Inc. Q3 2026 Earnings Call SummaryMoby · 02-13Vistagen Therapeutics Inc (VTGN) Q3 2026 Earnings Call Highlights: Progress in Clinical Trials ...GuruFocus.com · 02-13VistaGen Therapeutics, Inc. (VTGN) Reports Q3 Loss, Lags Revenue EstimatesZacks · 02-12
The file stays open
5 filings on record.
The next one will be too.
▸ SEC EDGAR · FINRA · Nasdaq — public sources only · research, not advice